Many patients using highly effective GLP-1 drugs may not regain lost weight quickly when they stop treatment, according to an analysis of real-world data that sheds light on a chief concern about the therapies.
Among thousands of patients treated at a large network of academic medical clinics in the United States, most had kept the weight off or lost even more 18 months after stopping semaglutide, sold by Novo Nordisk as Ozempic and Wegovy, or tirzepatide, sold by Eli Lilly as Mounjaro and...
Espace publicitaire · 300×250
